Form 4 for CTSO Cytosorbents Corp
Accepted 2025-01-22 00:00:00 ET · period of report 2025-01-17 · accession 0001104659-25-005354 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-22 | 2025-01-17 | CTSO | Sobel Alan D. | Dir | X - OptEx | $1.00 | +21.9K | 123.8K | +22% | +$21.9K |
| DM | 2025-01-22 | 2025-01-17 | CTSO | Sobel Alan D. | Dir | J - Other | — | +43.9K | 21.9K | New | — |
| D | 2025-01-22 | 2025-01-17 | CTSO | Sobel Alan D. | Dir | X - OptEx | $0.00 | -21.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-17 | X | A | 21,950 | $1.00 | 123,807 | D | — | — | (F1) On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date"). (F2) Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person. |
| 2 | Derivative | Series A Right Warrants | 2025-01-17 | J | A | 21,950 | — | 21,950 | D | — · 2025-01-17 to 2025-02-24 | 21,950 Common Stock | (F1) On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date"). (F4) The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00. (F5) The Series A Right Warrants expire 45 calendar days following the Closing Date. |
| 3 | Derivative | Series B Right Warrants | 2025-01-17 | J | A | 21,950 | — | 21,950 | D | — · 2025-01-17 to 2025-04-10 | 21,950 Common Stock | (F1) On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 21,950 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $21,950. The Rights Offering closed on January 10, 2025 (the "Closing Date"). (F6) The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00. (F7) The Series B Right Warrants expire 90 calendar days following the Closing Date. |
| 4 | Derivative | Subscription Rights (right to buy) | 2025-01-17 | X | D | 21,950 | $0.00 | 0 | D | $1.00 · 2024-12-09 to 2025-01-10 | 21,950 Common Stock |